Biological Lattice Industries Corp. (BLI), an innovator in biofabrication and life sciences, has closed a $1.8 million pre-seed funding round led by Greek venture capital firm Uni.Fund. Alongside this investment, BLI is launching its first integrated biofabrication solution: BioLoom™, a multi-tool 3D bioprinter, and Loominus Studio™, a unified software platform designed to streamline biofabrication workflows. The U.S.-based startup, with R&D operations in Greece, aims to simplify biofabrication for researchers worldwide by providing automated tools that optimize the design, fabrication, and testing of biomaterials used in applications such as advanced 3D cell cultures, resorbable medical devices, and drug delivery systems.
Founder and CEO Filippos Tourlomousis expressed enthusiasm for the partnership with Uni.Fund, emphasizing that the funding will accelerate the development of BLI’s platform, enabling more precise, reproducible, and efficient biofabrication.
Loominus Studio: A Unified Biofabrication Platform
Traditional biofabrication workflows involve multiple disconnected protocols and instruments. Loominus Studio™ addresses this challenge by integrating all aspects of the workflow, from design to fabrication, allowing researchers to automate complex processes, enhance reproducibility, and reduce optimization effort.
Tourlomousis highlighted the platform’s potential, stating, “Loominus Studio sets a new standard for biofabrication, enabling labs to focus on innovation instead of technical integration.”
BioLoom™: Expanding Bioprinting Capabilities
Central to BLI’s ecosystem is BioLoom™, a versatile extrusion-based 3D bioprinter capable of creating high-resolution, multi-material scaffolds and devices. The printer’s Active Environmental Control feature ensures reproducibility and supports Good Manufacturing Practice (GMP) compliance, making it suitable for both academic and commercial labs aiming to advance life sciences research and commercialization.
“BioLoom delivers unmatched precision and flexibility,” Tourlomousis added. “It’s designed to push biofabrication beyond the limits of traditional 3D bioprinting.”
Uni.Fund’s Role in Deep Tech Innovation
Uni.Fund sees BLI as a disruptor in biotech, with a vision to transform global biofabrication practices. “BLI’s integrated approach, combining advanced hardware, software, and AI, is the kind of deep tech innovation we aim to support,” said Katerina Pramatari, Founding Partner at Uni.Fund.
Shaping the Future of Biofabrication
BLI’s goal is to establish Loominus as the industry standard in biofabrication, with an expanding toolkit that simplifies complex workflows. The investment will speed up the market launch of BioLoom and Loominus Studio, which have already been adopted by leading academic labs through an early adopters program.
About Biological Lattice Industries (BLI): BLI is dedicated to democratizing biofabrication and advancing life sciences research through cutting-edge tools and integrated solutions.
About Biological Lattice Industries (BLI)
Biological Lattice Industries Corp. (BLI) is a venture-backed startup founded in 2021 with the goal of democratizing biofabrication for life sciences R&D. BLI’s platform, Loominus Studio, and its ecosystem of integrated hardware tools, including the BioLoom bioprinter, aim to revolutionize the way biomaterials are designed, fabricated, and tested.
